A political philosophy perspective argues that despite a libertarian preference for no regulation, the potential for catastrophic AI risks makes state involvement a "tragic necessity." The national security apparatus will not ignore weaponizable models, making controlled "perpetual interference" the only practical path.

Despite media reports, the idea of an "FDA for AI" that pre-approves models is not supported by key policy advisors. Insiders stress the goal is industry coordination to harden government systems against AI threats, not to create a Washington-based approval bottleneck that would kill innovation.

The Commerce Department's 'Casey' initiative is evaluating unreleased models from major labs like OpenAI and Google. This silent approval process could slow public releases, give government exclusive access, and create hurdles for new entrants, effectively forming a regulatory moat that benefits established players.

The "Genesis Mission" aims to use national labs' data and supercomputers for AI-driven science. This initiative marks a potential strategic shift away from the prevailing tech belief that breakthroughs like AGI will emerge exclusively from private corporations, reasserting a key role for government-led R&D in fundamental innovation.

The US government is restricting Anthropic's commercial rollout of its new model, Mythos, over concerns it could hamper the government's own access to compute. This move treats AI capacity as a strategic national resource and effectively creates a de facto licensing system for powerful models, marking a new era of AI governance.

The US nuclear weapons industry operates as a hybrid: the government owns the IP and facilities, but private contractors like Honeywell and Boeing operate them and build delivery systems. This established public-private partnership model could be applied to manage the risks of powerful, privately-developed AI.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.

The US and China view AI superiority as a national security imperative comparable to nuclear weapons, ensuring massive state funding. However, this creates a major risk for investors, as governments may eventually decide to nationalize or control leading AI companies for military purposes, compressing multiples.

The White House blocked Anthropic's plan to expand access to its Mythos model, citing compute constraints that could hamper government use. This signals a move towards "soft nationalization": exerting control over private AI resources without a formal takeover.